Kura Oncology KURA
NASDAQ KURA
$10.65 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Kura Oncology (KURA) Return on Sales [ROS] (2025 - 2026)

Updated

Kura Oncology (KURA) reported Return on Sales [ROS] of -349.77% for Q2 2026, up 125.55 percentage points from -475.31% a year earlier and up 81.74 percentage points from the prior quarter.

Analysis

Kura Oncology (KURA) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Kura Oncology's Return on Sales [ROS] came in at -396.41%; for FY2025, it came in at -449.94%, down 91.40 percentage points from FY2024.

  • By year, Return on Sales [ROS] came in at -358.55% in FY2024.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -431.51% (Q1 2026), -464.82% (Q4 2025) and -355.29% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Kura Oncology 947.36 Mn 947.36 Mn 20.63 Mn -349.77%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -349.77%
Mar 31, 2026 -431.51%
Dec 31, 2025 -464.82%
Sep 30, 2025 -355.29%
Jun 30, 2025 -475.31%
Mar 31, 2025 -458.61%
API Access

Kura Oncology Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=KURA&period=max&api_key=YOUR_API_KEY